The Pilot and Feasibility (P&F) Program of the Diabetes Research Center at the University of Washington promotes the development of new and innovative research directed at basic biomedical, clinical, behavioral and translational aspects of diabetes and its complications. The specific objectives of the Program are to: (1) Provide initial research support for promising junior faculty who have not yet had independent peer-reviewed NIH funding; (2) Provide pilot funding for established faculty entering the field of diabetes research for the first time; (3) Support pilot projects by established diabetes investigators proposing to pursue high impact/high risk projects or a novel direction in their diabetes related research; and (4) Foster mentored training in research related to diabetes by offering postdoctoral and graduate fellowships. The P&F Program annually awards $200,000 of the Center's NIDDK direct funds (a minimum of 20%) for P&F research projects. In addition, funds provided by the University are used to support new investigator research, translational research, training of postdoctoral fellows and graduate students, and service grants for junior investigators to use the Center's resources. Applications are peer-reviewed by external and internal reviewers and the Center's Executive Committee, with awards being made based on scientific merit and qualifications of the applicant, including the potential for subsequent external peer-reviewed funding. During the last decade (two funding cycles), NIDDK funds to the Diabetes Research Center at the University of Washington supported 26 P&F awards, the majority of which were awarded to junior faculty. Of these P&F-funded investigators, 25 remain active in research related to diabetes, obesity and related disorders (96% success). Thus, the P&F Program continues to be a highly successful component of the Diabetes Research Center that utilizes funds provided by NIDDK and the University of Washington to support new and innovative research in the area of diabetes, obesity and related disorders, and in this manner also fosters the career development of junior investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK017047-45
Application #
10077865
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2018-02-10
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Tanaka, Shigeru; Pfleger, Christian; Lai, Jen-Feng et al. (2018) KAP1 Regulates Regulatory T Cell Function and Proliferation in Both Foxp3-Dependent and -Independent Manners. Cell Rep 23:796-807
Houston, Denise K; Neiberg, Rebecca H; Miller, Michael E et al. (2018) Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. J Gerontol A Biol Sci Med Sci 73:1552-1559
Guo, Rui; Hua, Yinan; Ren, Jun et al. (2018) Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell Death Dis 9:692
van Zuydam, Natalie R; Ahlqvist, Emma; Sandholm, Niina et al. (2018) A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes 67:1414-1427
Hull, Rebecca L; Gibson, Ronald L; McNamara, Sharon et al. (2018) Islet Interleukin-1? Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to ?-Cell Failure. Diabetes Care 41:823-830
Koletzko, Sibylle; Lee, Hye-Seung; Beyerlein, Andreas et al. (2018) Cesarean Section on the Risk of Celiac Disease in the Offspring: The Teddy Study. J Pediatr Gastroenterol Nutr 66:417-424
Roe, Nathan D; Handzlik, Michal K; Li, Tao et al. (2018) The Role of Diacylglycerol Acyltransferase (DGAT) 1 and 2 in Cardiac Metabolism and Function. Sci Rep 8:4983
Chepurny, Oleg G; Bonaccorso, Ron L; Leech, Colin A et al. (2018) Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Sci Rep 8:3749
Wang, Yang; Sosinowski, Tomasz; Novikov, Andrey et al. (2018) C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes. Proc Natl Acad Sci U S A 115:162-167
Kikuchi, Shinsuke; Chen, Lihua; Xiong, Kevin et al. (2018) Smooth muscle cells of human veins show an increased response to injury at valve sites. J Vasc Surg 67:1556-1570.e9

Showing the most recent 10 out of 1296 publications